Our upgraded platform utilizes only mg amounts of API to screen amorphous solid dispersion technologies and now has extra screening capabilities for controlled and delayed release formulations. You can now evaluate and address formulation issues early on in the process. This saves crucial time and money.
The majority of current NCEs in pharmaceutical oral delivery pipelines, up to 70%, are BCS II with poor Aqueous Solubility. Another 20% are BCS III or IV with poor permeability.
With these statistics, the odds are high that your current pipeline products are suffering from poor aqueous solubility and/or poor permeability e.g. they have very low oral bioavailability.
Home
Download
